TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then immediately hatched a plan to replace it with a late-stage candidate for metabolic dysfunction-associated steatohepatitis ...

iTeos to shut down following $2bn GSK-partnered TIGIT asset failure iTeos will look to distribute its cash reserves to shareholders, along with proceeds raised from selling pipeline assets.

US biotech iTeos Therapeutics (Nasdaq: ITOS) is preparing to wind down its operations and halt clinical work, as it looks to sell off assets and return value to investors following a major blow to its ...

Summary iTeos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Here, we review why the TIGIT program of Arcus and Gilead could fail in lung ...

GSK, iTeos End Anti-TIGIT Drug Development In a separate press release, the company announced that it is ending the development of the anti-TIGIT antibody belrestotug, which was being developed in ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials.

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end development of the TIGIT-targeting antibody and halt enrollment in all ongoing ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer drug, belrestotug, after it failed to stop the disease from progressing ...